Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-03-05
DOI
10.3389/fonc.2021.596290
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
- (2020) Anthony R. Cillo et al. IMMUNITY
- Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
- (2020) R.L. Ferris et al. ANNALS OF ONCOLOGY
- Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
- (2020) Min Hwan Kim et al. BRITISH JOURNAL OF CANCER
- Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
- (2020) Hiro Sato et al. International Journal of Clinical Oncology
- An open-label, non-randomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): updated results of cohort 1 analysis
- (2020) A.G. Sacco et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study.
- (2020) Christine H. Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of the correlation between antibiotic use and survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs).
- (2020) Paz J. Vellanki et al. JOURNAL OF CLINICAL ONCOLOGY
- Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.
- (2020) Weimin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular correlates of response to preoperative olaparib alone or with cisplatin or with durvalumab in head and neck squamous cell carcinoma (HNSCC): A Hellenic Cooperative Oncology Group study.
- (2020) Amanda Psyrri et al. JOURNAL OF CLINICAL ONCOLOGY
- Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab.
- (2020) Enriqueta Felip et al. JOURNAL OF CLINICAL ONCOLOGY
- PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy
- (2020) Fabiana Conciatori et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis
- (2020) Daniel Lenouvel et al. ORAL ONCOLOGY
- Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes
- (2020) David M. Woods et al. JCI Insight
- LBA38 Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial
- (2020) J. Bourhis et al. ANNALS OF ONCOLOGY
- 910O Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)
- (2020) E.E. Cohen et al. ANNALS OF ONCOLOGY
- Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma
- (2020) Sean McBride et al. JOURNAL OF CLINICAL ONCOLOGY
- The immune phenotype of tongue squamous cell carcinoma predicts early relapse and poor prognosis
- (2020) Giuseppe Troiano et al. Cancer Medicine
- Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
- (2019) Junfei Zhao et al. NATURE MEDICINE
- Neoantigen-directed immune escape in lung cancer evolution
- (2019) Rachel Rosenthal et al. NATURE
- The immune subtypes and landscape of squamous cell carcinoma
- (2019) Bailiang Li et al. CLINICAL CANCER RESEARCH
- Preliminary effects on the innate immune system with the combination of cetuximab and durvalumab in metastatic/ relapsed head and neck squamous cell carcinoma in a phase II trial.
- (2019) Shuchi Gulati et al. JOURNAL OF CLINICAL ONCOLOGY
- The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancer
- (2019) Hao Chen et al. CANCER SCIENCE
- Expression of programmed death ligand (PD-L1) in different tumors. Comparison of several current available antibody clones and antibody profiling
- (2019) Svetlana Kintsler et al. Annals of Diagnostic Pathology
- The Immune Landscape of Cancer
- (2019) Vésteinn Thorsson et al. IMMUNITY
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial
- (2019) Joris B.W. Elbers et al. RADIOTHERAPY AND ONCOLOGY
- Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma
- (2019) Lei Wu et al. Cancer Immunology Research
- 440OPhase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours
- (2019) A Naing et al. ANNALS OF ONCOLOGY
- 1116PDA window of opportunity trial of preoperative nivolumab with or without tadalafil in squamous cell carcinoma of the head and neck (SCCHN): Safety, clinical, and correlative outcomes
- (2019) A J Luginbuhl et al. ANNALS OF ONCOLOGY
- 1129PWindow of opportunity for durvalumab (MEDI4736) plus metformin trial in squamous cell carcinoma of the head and neck (SCCHN): Interim safety analysis
- (2019) T Richa et al. ANNALS OF ONCOLOGY
- 1210PPhase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
- (2019) C Le Tourneau et al. ANNALS OF ONCOLOGY
- Tumor angiogenesis: causes, consequences, challenges and opportunities
- (2019) Roberta Lugano et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma
- (2019) Jonathan A. Trujillo et al. Journal for ImmunoTherapy of Cancer
- Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
- (2018) Ranee Mehra et al. BRITISH JOURNAL OF CANCER
- The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
- (2018) Vancheswaran Gopalakrishnan et al. CANCER CELL
- Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy
- (2018) Florent Amatore et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- The Immune Landscape of Cancer
- (2018) Vésteinn Thorsson et al. IMMUNITY
- Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma
- (2018) Y. Maruse et al. INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
- Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
- (2018) Robert L. Ferris et al. ORAL ONCOLOGY
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
- (2018) Laurence Zitvogel et al. SCIENCE
- Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
- (2018) Marco B. Schaaf et al. Cell Death & Disease
- Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging
- (2018) Chia-Yu Yang et al. Frontiers in Microbiology
- Drinking alcohol is associated with variation in the human oral microbiome in a large study of American adults
- (2018) Xiaozhou Fan et al. Microbiome
- Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
- (2018) Jun Gong et al. Journal for ImmunoTherapy of Cancer
- Abstract CT098: Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
- (2018) Ezra Cohen et al. CANCER RESEARCH
- ICOS-L as a Potential Therapeutic Target for Cancer Immunotherapy
- (2018) Oliviero Marinelli et al. CURRENT PROTEIN & PEPTIDE SCIENCE
- VSIG-3 as a ligand of VISTA inhibits human T cell function
- (2018) Jinghua Wang et al. IMMUNOLOGY
- Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
- (2018) Tara C. Mitchell et al. JOURNAL OF CLINICAL ONCOLOGY
- ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers.
- (2018) Timothy Anthony Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck.
- (2018) Matthew H. Taylor et al. JOURNAL OF CLINICAL ONCOLOGY
- Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
- (2018) Andrea Botticelli et al. Journal of Translational Medicine
- Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer
- (2018) Erminia Massarelli et al. JAMA Oncology
- 1138PDFirst in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1
- (2018) A Hansen et al. ANNALS OF ONCOLOGY
- 1044OA phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results
- (2018) E E W Cohen et al. ANNALS OF ONCOLOGY
- Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy
- (2018) Y -P Chen et al. ANNALS OF ONCOLOGY
- PD-L1 expression in tumor cells is an independent unfavorable prognostic factor in oral squamous cell carcinoma
- (2018) Juan C de Vicente et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
- (2018) Jun Wang et al. CELL
- Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
- (2018) Dan P. Zandberg et al. EUROPEAN JOURNAL OF CANCER
- PI3‐kinase pathway biomarkers in oral cancer and tumor immune cells
- (2018) Mohammad Y. Ibrahim et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- (2018) Ezra E W Cohen et al. LANCET
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
- (2018) Lillian L. Siu et al. JAMA Oncology
- Galectin-9: Diverse roles in hepatic immune homeostasis and inflammation
- (2017) Lucy Golden-Mason et al. HEPATOLOGY
- Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
- (2017) Suzanne George et al. IMMUNITY
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
- (2017) Joshua Bauml et al. JOURNAL OF CLINICAL ONCOLOGY
- Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
- (2017) Hojabr Kakavand et al. MODERN PATHOLOGY
- T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer
- (2017) Jian-Feng Liu et al. Molecular Oncology
- Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck
- (2017) Astrid De Meulenaere et al. ORAL ONCOLOGY
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
- (2017) Teresa Davoli et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
- (2017) Whijae Roh et al. Science Translational Medicine
- Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation
- (2017) Veronica Huber et al. SEMINARS IN CANCER BIOLOGY
- Microbiota dysbiosis in select human cancers: Evidence of association and causality
- (2017) Jie Chen et al. SEMINARS IN IMMUNOLOGY
- Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers
- (2017) Chan-Young Ock et al. Nature Communications
- Resistance to checkpoint blockade therapy through inactivation of antigen presentation
- (2017) Moshe Sade-Feldman et al. Nature Communications
- Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
- (2017) Scott Gettinger et al. Cancer Discovery
- Microbial Communities Associated with Primary and Metastatic Head and Neck Squamous Cell Carcinoma – A High Fusobacterial and Low Streptococcal Signature
- (2017) Jae M. Shin et al. Scientific Reports
- A comparative study of PD-L1 diagnostic assays in squamous cell carcinoma of the head and neck (SCCHN)
- (2016) M.J. Ratcliffe et al. ANNALS OF ONCOLOGY
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
- (2016) Marco Ruella et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
- (2016) Jeffrey S Weber et al. LANCET ONCOLOGY
- Neoantigen landscape dynamics during human melanoma–T cell interactions
- (2016) Els M. E. Verdegaal et al. NATURE
- Erratum: Corrigendum: High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma
- (2016) Carsten Linnemann et al. NATURE MEDICINE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
- (2016) David H. Munn et al. TRENDS IN IMMUNOLOGY
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma
- (2016) Wei-Wei Deng et al. OncoImmunology
- Innate Immune Recognition of Cancer
- (2015) Seng-Ryong Woo et al. Annual Review of Immunology
- Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer
- (2015) L. Corrales et al. CLINICAL CANCER RESEARCH
- Immunology and Immunotherapy of Head and Neck Cancer
- (2015) Robert L. Ferris JOURNAL OF CLINICAL ONCOLOGY
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
- (2015) Jun Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Glycoprotein B7-H3 overexpression and aberrant glycosylation in oral cancer and immune response
- (2015) Jung-Tsu Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
- (2015) E. Sotillo et al. Cancer Discovery
- Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
- (2015) Rikke B. Holmgaard et al. Cell Reports
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
- (2014) Rakesh K. Jain CANCER CELL
- LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
- (2014) F. Xu et al. CANCER RESEARCH
- Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
- (2014) S. D. Brown et al. GENOME RESEARCH
- Regulatory T Cells Control Antigen-Specific Expansion of Tfh Cell Number and Humoral Immune Responses via the Coreceptor CTLA-4
- (2014) James Badger Wing et al. IMMUNITY
- Therapeutic use of anti-CTLA-4 antibodies
- (2014) C. U. Blank et al. INTERNATIONAL IMMUNOLOGY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma
- (2014) Carsten Linnemann et al. NATURE MEDICINE
- The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck
- (2014) Dan P. Zandberg et al. ORAL ONCOLOGY
- Control of the Adaptive Immune Response by Tumor Vasculature
- (2014) Laetitia Mauge et al. Frontiers in Oncology
- Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
- (2013) S. Lyford-Pike et al. CANCER RESEARCH
- Immune alterations and immunotherapy prospects in head and neck cancer
- (2013) Vincent Varilla et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities
- (2013) Monika E. Freiser et al. IMMUNOLOGIC RESEARCH
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
- (2013) Paul F Robbins et al. NATURE MEDICINE
- Targeted Deletion of Fibrinogen Like Protein 1 Reveals a Novel Role in Energy Substrate Utilization
- (2013) Valeriy Demchev et al. PLoS One
- Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy
- (2013) Chao Ma et al. Cancer Discovery
- GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability
- (2013) D. A. Schaer et al. Cancer Immunology Research
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†
- (2012) M. Reck et al. ANNALS OF ONCOLOGY
- Immuno-oncology: understanding the function and dysfunction of the immune system in cancer
- (2012) O. J. Finn ANNALS OF ONCOLOGY
- Innate immune sensing of cancer: clues from an identified role for type I IFNs
- (2012) Thomas F. Gajewski et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer
- (2012) Charles C. L. Tong et al. IMMUNOLOGIC RESEARCH
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
- (2012) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- The TIGIT/CD226 Axis Regulates Human T Cell Function
- (2012) E. Lozano et al. JOURNAL OF IMMUNOLOGY
- Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
- (2011) Q. Zhou et al. BLOOD
- Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
- (2011) Li Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- (2011) Omid Hamid et al. Journal of Translational Medicine
- A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells
- (2011) Chao Ma et al. NATURE MEDICINE
- PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells
- (2009) Wenshi Wang et al. INTERNATIONAL IMMUNOLOGY
- Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma
- (2009) Luis H. Camacho et al. JOURNAL OF CLINICAL ONCOLOGY
- Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma
- (2008) Y Mizukami et al. BRITISH JOURNAL OF CANCER
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More